Synthetic Biology Company Hits Tech-Transfer Ready Targeted Timeline

A next generation therapeutics company was looking to develop a novel gene modified cell-based therapy that can be delivered to patients as efficiently and safely as possible.

To navigate through the complex product and process development stages of this novel therapeutic, their team needed to find the right partner who can provide them with cellular starting materials for MSC manufacturing and has the expertise to help them create a robust process that can produce a successful product.

RoosterBio supplied off-the-shelf RUO and cGMP hMSC starting materials in formats that accelerated their product and process development efforts. By working closely with the Company team, RoosterBio helped train their scientists and develop a manufacturing process that met their production needs for a Phase I requirement.